newsBaricitinibbiomarkers
Serum Proteomic Changes Correlate with Baricitinib Efficacy in Juvenile Idiopathic Arthritis: Evidence from the JUVE-BASIS Trial
By MedXY|Jan 13, 2026
A post-hoc analysis of the Phase 3 JUVE-BASIS trial identifies key serum biomarkers, including CCL7, CCL18, and IL-6, that correlate with clinical response to baricitinib in JIA, suggesting potential pathways for personalized JAK inhibitor
